Cover Image
Market Research Report

Investigation Report on China's Irbesartan Market, 2018-2022

Published by China Research and Intelligence Product code 699012
Published Content info 30 Pages
Delivery time: 1-2 business days
Price
Back to Top
Investigation Report on China's Irbesartan Market, 2018-2022
Published: September 14, 2018 Content info: 30 Pages
Description

Sartans are antihypertensive drugs with highly selective, effective and long-lasting multi-organ targeted protection. With a more specific mechanism of action, they prevent dry cough and other side effects that may be caused by angiotensin-converting enzyme inhibitors (ACEIs), and thus have replaced the ACEIs in some clinical uses. As a result, the growth of the ACEI market slows down, which leading to a steady increase in the Sartans market. Another growth driver is the new edition of List of Medicines Covered by National Basic Medical Insurance that included compound preparations.

Irbesartan was developed by Sanofi, first approved by the European Medicines Agency (EMA) on Aug. 27, 1997, and then approved by the U.S. Food and Drug Administration (FDA) on Sept. 30, 1997. The trade name of Sanofi's Irbesartan is Aprovel. Irbesartan is mainly used to treat primary hypertension and has little effect on heart rate. Irbesartan can also protect kidneys and slow the progression of diabetic nephropathy. It can slow the progression of kidney disease for patients with both type 2 diabetic nephropathy and hypertension.

According to CRI, domestic enterprises developed the generic versions of Aprovel early. The generic drugs were approved to be sold in China in 2000. By Sept. 2018, there are 11 Irbesartan API manufacturers, and 24 manufacturers of Irbesartan tablets, capsules and dispersible tablets in China. The Irbesartan products of Sanofi and its subsidiary Sanofi (Hangzhou) Pharmaceutical Co., Ltd. Have an absolute advantage in China, taking up approximately 80% market share by sales value in 2017.

There were about 330 million hypertensive patients in China at the end of 2017. One in every three adults has high blood pressure. Chinese hypertensive patients account for about one-third of the global total. The incidence of hypertension in China rose by 32.1% from 5.1% in 1959 to 37.2% in 2017.

The sales value of Irbesartan was on the rise after it entered China, exceeding CNY 300 million in 2017. It is expected that the market size will continue to grow from 2018 to 2022 with the increasing number of hypertensive patients.

Topics Covered:

  • Development environment of China's Irbesartan market
  • Market demand for Irbesartan in China
  • Analysis on competition on China's Irbesartan market
  • Analysis on major Irbesartan manufacturers in China
  • Driving forces for China's Irbesartan market from 2018 to 2022
  • Prospect of China's Irbesartan market from 2018 to 2022
Table of Contents
Product Code: 1809339

Table of Contents

1. Relevant Concepts of Irbesartan

  • 1.1. Indications for Irbesartan
  • 1.2. Development History of Irbesartan in China
  • 1.3. Governmental Approval of Irbesartan in China

2. Sales of Irbesartan in China, 2013-2017

  • 2.1. Sales Value
    • 2.1.1. Overall Sales Value
    • 2.1.2. Sales Value by Region
  • 2.2. Sales Volume
    • 2.2.1. Overall Sales Volume
    • 2.2.2. Sales Volume by Region
  • 2.3. Sales of Irbesartan by Dosage Form in China, 2013-2017
    • 2.3.1. Tablets
    • 2.3.2. Capsules

3. Analysis on Major Competitors on China's Irbesartan Market, 2013-2017

  • 3.1. Analysis on Market Share of Major Irbesartan Manufacturers
    • 3.1.1. Market Share by Sales Value
    • 3.1.2. Market Share by Sales Volume
  • 3.2. Sanofi (Hangzhou) Pharmaceutical Co., Ltd.
    • 3.2.1. Enterprise Profile
    • 3.2.2. Sales of Sanofi (Hangzhou) Pharmaceutical Co., Ltd.'s Irbesartan in China9
  • 3.3. Sanofi
    • 3.3.1. Enterprise Profile
    • 3.3.2. Sales of Sanofi's Irbesartan in China
  • 3.4. Jiangsu Hengrui Medicine Co., Ltd.
    • 3.4.1. Enterprise Profile
    • 3.4.2. Sales of Jiangsu Hengrui Medicine Co., Ltd.'s Irbesartan in China
  • 3.5. Zhuhai Rundu Pharmaceutical Co., Ltd.
  • 3.6. Weifang Zhongshi Pharmaceutical Co., Ltd.

4. Prices of Irbesartan in China, 2017-2018

  • 4.1. Sanofi (Hangzhou) Pharmaceutical Co., Ltd. (Aprovel)
  • 4.2. Sanofi (Aprovel)
  • 4.3. Jiangsu Hengrui Medicine Co., Ltd. (Jijia)
  • 4.4. Zhuhai Rundu Pharmaceutical Co., Ltd. (Yitaiqing)
  • 4.5. Weifang Zhongshi Pharmaceutical Co., Ltd. (Bida)

5. Prospect of China's Irbesartan Market, 2018-2022

  • 5.1. Forecast on Market Size
  • 5.2. Forecast on Market Trend

Selected Charts

  • Chart Sales of Irbesartan in China, 2013-2017
  • Chart Sales Value of Irbesartan in Parts of China, 2013-2017
  • Chart Sales Volume of Irbesartan in China, 2013-2017
  • Chart Sales Volume of Irbesartan in Parts of China, 2013-2017
  • Chart Sales Value of Irbesartan Tablets in China, 2013-2017
  • Chart Sales Value of Irbesartan Capsules in China, 2013-2017
  • Chart Market Share of Top 5 Irbesartan Manufacturers by Sales Value in China, 2013-2017
  • Chart Market Share of Top 5 Irbesartan Manufacturers by Sales Volume in China, 2013-2017
  • Chart Profile of Sanofi (Hangzhou) Pharmaceutical Co., Ltd.
  • Chart Sales Value of Sanofi (Hangzhou) Pharmaceutical Co., Ltd.'s Irbesartan, 2013-2017
  • Chart Profile of Sanofi
  • Chart Sales Value of Sanofi's Irbesartan in China, 2013-2017
  • Chart Sales Value of Jiangsu Hengrui Medicine Co., Ltd.'s Irbesartan, 2013-2017
  • Chart Prices of Sanofi (Hangzhou) Pharmaceutical Co., Ltd.'s Irbesartan in Parts of China, 2017-2018
  • Chart Prices of Sanofi's Irbesartan in Parts of China, 2017-2018
  • Chart Prices of Jiangsu Hengrui Medicine Co., Ltd.'s Irbesartan in Parts of China, 2017-2018
  • Chart Forecast on Sales Value of Irbesartan in China, 2018-2012
Back to Top